Morepen Secures ₹825 Crore Global CDMO Deal

Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has announced a landmark ₹825 crore CDMO contract with a global pharmaceutical giant. This multi-year mandate underscores Morepen’s growing credibility in regulated markets and expands its footprint in long-duration supply programs.

The company will commence supplies within 4–5 months, with execution scheduled through Q1 of the next financial year. Backed by USFDA, WHO-GMP, and EU-approved facilities, Morepen is positioned to deliver complex scale-ups and long-term manufacturing solutions.

Key Highlights

• Deal Value: ₹825 crore (USD 91 million).
• Segment Expansion: Strengthens entry into high-growth CDMO segment.
• Execution Timeline: Supplies to begin in 4–5 months; execution in Q1 FY2027.
• Global Credibility: Facilities accredited by USFDA, WHO-GMP, and EU regulators.
• Leadership View: Chairman Sushil Suri emphasized the milestone as a natural extension of API strengths.
• Strategic Impact: Enhances scale, stability, and long-term value creation in global pharma partnerships.

Sources: Morepen Laboratories Ltd official press release (NSE & BSE filing, Feb 23, 2026).